Morgan Stanley
ANAC

Morgan Stanley’s ANACOR PHARMACEUTICALS INC COM ANAC Stock Holding History

Morgan Stanley’s Portfolio ANAC Stock Details ANAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-321,510
Closed -$17.2M – 7031
2016
Q1 		$17.2M Buy
321,510
+218,519
+212% +$16.1M 0.01% 1422
2015
Q4 		$11.6M Sell
102,991
-39,968
-28% -$4.4M ﹤0.01% 1838
2015
Q3 		$16.8M Sell
142,959
-49,528
-26% -$6.47M 0.01% 1527
2015
Q2 		$14.9M Buy
192,487
+19,355
+11% +$1.27M 0.01% 1744
2015
Q1 		$10M Buy
173,132
+101,557
+142% +$4.31M ﹤0.01% 2059
2014
Q4 		$2.31M Buy
71,575
+23,686
+49% +$711K ﹤0.01% 3445
2014
Q3 		$1.17M Sell
47,889
-57,558
-55% -$1.17M ﹤0.01% 3907
2014
Q2 		$1.87M Buy
105,447
+56,167
+114% +$904K ﹤0.01% 3539
2014
Q1 		$986K Buy
49,280
+17,734
+56% +$344K ﹤0.01% 4001
2013
Q4 		$530K Buy
31,546
+18,093
+134% +$250K ﹤0.01% 4412
2013
Q3 		$143K Sell
13,453
-10,289
-43% -$90K ﹤0.01% 5000
2013
Q2 		$132K Buy
+23,742
New +$144K ﹤0.01% 5007

Other funds holding ANAC

KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
CIM
CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return

Morgan Stanley's ANAC Position: Q2 2016 in Review

Morgan Stanley sold out of ANACOR PHARMACEUTICALS INC COM (ANAC) in Q2 2016, closing a stake of 321,510 shares — an estimated $17.2M sold.

Morgan Stanley first reported a position in ANAC in Q2 2013 and held it in 12 quarters. The position peaked at $17.2M in Q1 2016. 2 funds tracked by Wall St. Rank hold ANAC as of Q2 2016.

  • Morgan Stanley reported no remaining ANACOR PHARMACEUTICALS INC COM position as of Q2 2016 after selling out during the quarter.
  • Morgan Stanley sold 321,510 ANACOR PHARMACEUTICALS INC COM shares in Q2 2016, an estimated $17.2M.
  • Morgan Stanley first reported a position in ANACOR PHARMACEUTICALS INC COM in Q2 2013 and held it in 12 quarters.
  • Morgan Stanley's ANACOR PHARMACEUTICALS INC COM position peaked at $17.2M in Q1 2016.
  • 2 funds tracked by Wall St. Rank held ANACOR PHARMACEUTICALS INC COM as of Q2 2016.

Based on Morgan Stanley's 13F filing for Q2 2016, filed 12 Aug 2016.